ALX Oncology Announces November 2020 Virtual Investor Conference Participation
02 Novembre 2020 - 1:00PM
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a
clinical-stage immuno-oncology company developing therapies that
block the CD47 checkpoint pathway, today announced that Jaume Pons,
Ph.D., Founder, President and Chief Executive Officer and other
senior executives, will participate in two virtual investor
conferences in November.
29th
Annual Credit Suisse Virtual Healthcare
ConferenceFormat: Fireside chat with covering analyst,
Martin Auster, M.D.Date: Monday, November 9Time: 11:45 AM Eastern
TimeWebcast link: Available here
Jefferies Virtual London Healthcare
ConferenceFormat: Fireside chat with covering analyst,
Michael YeeDate: Thursday, November 19Time: 1:10 PM Eastern
TimeWebcast link: Available here
A live webcast of the fireside chats can be
accessed by visiting the Investors section of ALX Oncology’s
website at www.alxoncology.com and selecting the Investor Calendar
under the News and Events tab. A replay of the webcasts will be
archived for up to 90 days following the presentation dates.
About ALX
Oncology
ALX Oncology is a publicly traded,
clinical-stage immuno-oncology company focused on helping patients
fight cancer by developing therapies that block the CD47 checkpoint
pathway and bridge the innate and adaptive immune system. ALX
Oncology’s lead product candidate, ALX148, is a next generation
CD47 blocking therapeutic that combines a high-affinity CD47
binding domain with an inactivated, proprietary Fc domain. ALX148
has demonstrated promising clinical responses across a range of
hematologic and solid malignancies in combination with a number of
leading anti-cancer agents. ALX Oncology intends to continue
clinical development of ALX148 for the treatment of a range of
solid tumor indications and myelodysplastic syndromes. For more
information, please visit ALX Oncology’s website at
https://www.alxoncology.com.
Investor Contact:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Argot Partners
(212)-600-1902
alxoncology@argotpartners.com
Media Contact:
Karen Sharma
MacDougall
(781) 235-3060
alx@macbiocom.com
Grafico Azioni ALX Oncology (NASDAQ:ALXO)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni ALX Oncology (NASDAQ:ALXO)
Storico
Da Lug 2023 a Lug 2024